NCT00482196已完成2 期
To Study Different Levels of MK0493 for Safety, Efficacy, and Tolerability in Obese Patients (0493-017)(COMPLETED)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 173
研究概览
简要总结
To study different doses of MK0493 for safety, efficacy and tolerability in obese patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 21 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is between 21 and 65 years of age
排除标准
- •HIV positive as determined by medical history
- •Patient is pregnant, lactating or plans to become pregnant
- •Patient has undergone surgical treatment for obesity
- •Patient has undergone a surgical procedure within 4 weeks prior to Visit 1 or plans to undergo a surgical procedure during the study
- •Patient plans to consume more than 2 glasses of grapefruit juice per day during the study
- •Patient has participated in another clinical study (involving an investigational drug) within 3 months prior to restudy screening
研究者
相似试验
已完成
1 期
A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])Alzheimer's DiseaseNCT01496170Merck Sharp & Dohme LLC32
已完成
2 期
Study of Safety, Tolerability and Efficacy of MK0493 in Obese Patients (0493-008)(COMPLETED)ObesityNCT00482638Merck Sharp & Dohme LLC
终止
2 期
Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)Diabetes Mellitus Type 2NCT00543959Merck Sharp & Dohme LLC346
终止
1 期
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002)Hepatitis C, ChronicNCT01554189Merck Sharp & Dohme LLC37
已完成
1 期
MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)SchizophreniaNCT02181803Merck Sharp & Dohme LLC55